Order Article Reprints

Eda T, Okada M, Ogura R, Tsukamoto Y, Kanemaru Y, Watanabe J, On J, Aoki H, Oishi M, Takei N, et al. Novel Repositioning Therapy for Drug-Resistant Glioblastoma: In Vivo Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide. Cancers. 2022; 14(3):770. https://doi.org/10.3390/cancers14030770

Eda, Takeyoshi, Masayasu Okada, Ryosuke Ogura, Yoshihiro Tsukamoto, Yu Kanemaru, Jun Watanabe, Jotaro On, Hiroshi Aoki, Makoto Oishi, Nobuyuki Takei, and et al. 2022. "Novel Repositioning Therapy for Drug-Resistant Glioblastoma: In Vivo Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide" Cancers 14, no. 3: 770. https://doi.org/10.3390/cancers14030770

Eda, T., Okada, M., Ogura, R., Tsukamoto, Y., Kanemaru, Y., Watanabe, J., On, J., Aoki, H., Oishi, M., Takei, N., Fujii, Y., & Natsumeda, M. (2022). Novel Repositioning Therapy for Drug-Resistant Glioblastoma: In Vivo Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide. Cancers, 14(3), 770. https://doi.org/10.3390/cancers14030770